RLF Relief Therapeutics

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Relief Therapeutics Holding SA / Key word(s): Conference
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

01.09.2023 / 07:45 CET/CEST


Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GENEVA (SEPT. 1, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that Jack Weinstein, chief executive officer, will present a company overview during the taking place September 11-13, 2023 at the Lotte New York Palace hotel in New York.

Presentation Date: Wednesday, Sept. 13, 2023
Presentation Time: 12:30 p.m. EDT
Location: Lotte New York Palace Hotel, 455 Madison Avenue at 50th Street, New York, NY 10022

Management will host one-on-one meetings during the event. Institutional investors who are registered for the conference can log into to request a meeting with the company.

A live webcast of the Relief Therapeutics presentation can be found at the following link: and will be archived for a period of 90 days after the conference.

ABOUT RELIEF THERAPEUTICS

is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics' portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas, which include rare metabolic, rare dermatology and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing to distribution partners. Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website  or follow Relief Therapeutics on  and . 

CONTACT:

RELIEF THERAPEUTICS Holding SA
Catherine Day, Vice President, Investor Relations & Communications


Additional features:

File:


End of Media Release


Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: 6
E-mail:
Internet:
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1716613

 
End of News EQS News Service

1716613  01.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1716613&application_name=news&site_id=research_pool
EN
01/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relief Therapeutics

Relief Therapeutics Holding S.A.: 1 director

A director at Relief Therapeutics Holding S.A. sold 8,028 shares at 3.863CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

 PRESS RELEASE

Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Con...

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 18.09.2024 / 07:00 CET/CEST Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024   GENEVA (SEPT. 18, 2024) – (SIX: , OTCQB: , ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has completed dosing in its ...

 PRESS RELEASE

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at...

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 02.09.2024 / 07:00 CET/CEST Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 GENEVA (SEPT. 2, 2024) – (SIX: , OTCQB: , ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced today that interim data from its clinical trial evaluating PKU GOLIKE® will be presented at the (SSIEM) 2024 Annual Symposium ...

 PRESS RELEASE

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary Gene...

Relief Therapeutics Holding SA / Key word(s): AGMEGM RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting 26.04.2024 / 17:30 CET/CEST RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority GENEVA (APR. 26, 2024) – (SIX: , OTCQB: , ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announces the results of the extraordinary general ...

 PRESS RELEASE

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual ...

Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference 01.09.2023 / 07:45 CET/CEST Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference GENEVA (SEPT. 1, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that Jack Weinstein, chief executive officer, will present a company overview during...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch